PARP1 and neoplasm: In addition, preventing DNA repair through inhibition of PARP1/2 sensitizes tumor cells to radiotherapy and cytotoxic drugs that damage DNA, establishing a rationale for using PARP inhibitors as anticancer agents in combination therapy [14, 20].